Biovail To Complete Sales Force Reorganization In April; Adds Specialty Reps
This article was originally published in The Pink Sheet Daily
Increased SG&A expenses associated with the sales force reorganization caused Biovail to miss its 2003 financial guidance. The company expects to out-license tramadol and once-daily metformin.
You may also be interested in...
The company revises its revenue guidance to $820-$920 mil. from $800-$940 mil. Estimate reflects stronger than expected Wellbutrin XL growth as well as lagging Cardizem LA, Teveten and Zovirax sales.
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.